全球周邊血栓管理市場：市場規模、佔有率和趨勢分析（2026-2032 年）

全球周邊血栓管理市場報告

2025年全球周邊血栓治療市場規模為13億美元。在預測期內，該市場預計將以7.3%的複合年成長率成長，到2032年將達到22億美元。

• 這份關於全球周邊血栓治療市場的綜合報告涵蓋七個區域：北美、拉丁美洲、西歐、中東歐、中東、亞太地區和非洲。報告針對每個區域提供詳細的市場評估、銷售量分析和平均售價數據，並預測至2032年，展望市場未來的發展前景。本說明的結構和流程與附件中的範例文件一致，並針對周邊血栓治療市場的流程、競爭格局和價格趨勢進行了調整。

本報告對全球周邊血栓治療市場進行了詳細分析，包括截至2022年的歷史數據，以及銷售量、手術量、平均售價、市場規模、市場佔有率、成長趨勢和至2032年的預測。報告還分析了近期併購、公司概況、產品系列和主要競爭對手。市場進一步細分為傳統血栓除去裝置、藥物血栓除去裝置和導管導引溶栓療法。

在血管介入治療中，周邊血栓的管理變得日益重要。這是因為醫生擴大採用微創血管內治療方法來清除或溶解周邊動脈和靜脈的血栓。這些手術相比傳統開放性手術創傷較小，有助於加快治療速度、縮短住院時間，並推動影像導引介入治療的廣泛應用。隨著器械技術的進步和手術經驗的積累，這些方法正逐漸成為某些血栓性疾病的標準治療方法。

此外，醫師偏好的改變也正在重塑市場格局。雖然溶栓療法在許多情況下仍然更具成本效益，但機械取栓術的臨床優勢正推動其應用日益廣泛。這些優勢包括更快的再灌注、更短的治療時間以及避免與溶栓藥物相關的出血風險。同時，新型高性能器械的出現推高了平均售價，尤其是在深層靜脈栓塞症和肺動脈栓塞的治療領域。

市場概覽

全球周邊血栓管理市場包括用於清除、破碎或溶解周邊動脈和靜脈血栓的器械和技術。這些器械廣泛應用於各種手術場景，包括深層靜脈栓塞症、肺動脈栓塞、維持透析通路以及其他需要快速恢復血管通暢的血栓性血管疾病。

這個市場正處於緊迫性、效率和手術技術進步的交會點。在許多血栓症病例中，時間至關重要。再灌注延遲會加重組織缺血，延長住院時間，並增加併發症的風險。因此，醫生們正日益尋求能夠更快完成血栓切除術，同時又能克服單獨使用溶栓藥物一些限制的工具。這正是推動治療方式從單純藥物治療轉向結合機械和藥物機械干預的更廣泛治療方法的因素之一。

此外，微創治療這一大趨勢也影響著這個市場。血管內治療因其創傷小、恢復期短，且能自然融入現代介入治療流程，如今已成為多種血管疾病的首選治療方案。周邊血栓管理裝置恰好契合了這個趨勢。它們使醫生能夠透過導管介入而非開放性手術來治療血栓，通常能更好地控制血栓並加快治療速度。

此外，人們對靜脈疾病和肺動脈栓塞日益成長的關注也影響著市場格局。傳統上，許多血管器械市場都專注於動脈介入治療。然而，如今，深層靜脈栓塞症（DVT）和肺動脈栓塞（PE）的治療正變得越來越具有商業性價值，尤其是在新型血栓切除系統能夠直接針對這些疾病，無需依賴溶栓劑即可實現更快速的手術之後。這正在改變市場的競爭格局和價值結構。

整體而言，周邊血栓管理市場正朝著更快、更精準、創傷更小的血栓治療方法轉變。這項轉變正推動周邊血管器械領域出現最強勁的成長趨勢之一。

市場促進因素

機械取栓術的優勢

全球周邊血栓治療市場最重要的促進因素之一是機械取栓術的臨床優勢。雖然藥物溶栓療法在初始成本方面可能更具成本效益，但機械取栓術具有許多優勢，這些優勢在實際臨床實踐中變得越來越重要。

部分患者無法接受溶栓治療或溶栓效果不佳。在這種情況下，機械取栓術成為更實用的解決方案。此外，在肢體缺血或其他緊急情況下，機械性取栓術比溶栓治療更快恢復血流。更快的再灌注可以減少後續併發症，縮短住院時間，從而改善患者和醫護人員的整體治療體驗。

另一項主要優勢在於減少了對溶栓劑的依賴。由於溶栓劑出血風險較高，許多醫生現在更謹慎地選擇何時使用。機械取栓術使醫生在許多情況下能夠避免或減少溶栓劑的使用，從而增強了他們對治療複雜病例的信心。隨著取栓術的普及，市場也受惠於平均售價的上漲，尤其是在採用高階設備而非低成本溶栓療法時，這一趨勢更為明顯。

血液透析患者數量增加

需要血液透析的患者數量不斷增加，也是市場需求的重要促進因素。隨著人口老化和肥胖率上升，糖尿病盛行率不斷攀升，導致腎衰竭患者數量持續增加。這進而引發了對透析通路手術和通路維護日益成長的需求。

血栓管理裝置在恢復或維持透析通路通暢性發揮重要作用。隨著全球透析患者群體不斷擴大，對動靜脈（AV）通路治療的需求也不斷成長。這凸顯了血栓切除術及相關介入措施的持續必要性，尤其是在維持通路通暢對患者長期管理至關重要的環境中。

微創血管內治療方法的廣泛應用

更廣泛的結構性因素是微創血管內血栓治療的日益普及。醫生擴大採用導管介入的方式進行血栓切除和溶栓治療，而不是依賴開放性手術或純粹的保守治療。這一趨勢與醫學界更關注縮短恢復時間、減輕手術帶來的身體負擔以及提高治療效率的理念相契合。

隨著血管內治療技術的進步，這些手術在臨床實踐中正被越來越廣泛地接受。此外，某些血栓性疾病的治療方法也日益標準化。這一點意義重大，因為它顯示市場不僅受益於醫療設備的創新，也受益於血栓管理實務本身的全面變革。

市場限制

資本設備

全球周邊血栓治療市場面臨的最大阻礙因素之一是某些設備系統所需的資本投入。某些血栓切除平台依賴配套的主機、幫浦和其他硬體。這不僅增加了初始成本，也佔了空間，而醫院和介入手術室的空間往往十分有限。

對於預算緊張或場地有限的醫療機構而言，這可能成為推廣應用程式的一大障礙。即使一次性醫療器材的臨床價值顯而易見，但對配套設備的需求也會使採購決策變得複雜。對於非大型醫療中心或手術量不足以支撐投資的市場而言，這種情況尤其突出。

與替代療法相比，高成本

另一個主要阻礙因素是血栓切除術的費用，與其他治療方法相比，血栓切除術的費用較高。血栓切除術的費用可能遠高於藥物治療、球囊血管成形術、支架置入術，甚至比使用引導管和長鞘套進行簡單的手動抽吸術還要昂貴。醫院仍然高度重視成本，並且通常在臨床上可接受的情況下選擇成本較低的替代方案。

這為高階血栓切除裝置的普及應用設定了一個合理的上限。即使在快速成長的市場中，也並非所有血栓症病例都會採用高階血栓除去裝置。醫院和醫生始終在速度、療效、風險和成本之間權衡取捨。換句話說，高價值裝置必須根據具體病例，與更簡單、更經濟的替代方案進行比較，才能證明其價值所在。

自發性瘻管偏好

尤其在歐洲，天然動靜脈瘻管仍是透析通路的首選方式。天然動靜脈瘻管的通暢率通常高於人工血管，從而減少了後續血栓切除術的需求。然而，在某些市場，這反而成為透析通路維護的限制因素。

在監管和使用方面也存在一些細微差別。機械血栓除去裝置通常主要核准用於人工血管移植，而用於自發性動靜脈瘺可能屬於超適應症用藥。雖然自發性動靜脈瘻管有時可能仿單標示外適合機械血栓切除術而非藥物治療，但由於人們普遍傾向於建立動靜脈瘺，因此與人工血管移植市場相比，血管通路相關的血栓介入治療的總體頻率仍然較低。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性範圍

市場促進因素和限制因素、成長趨勢、近期併購、公司概況、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料：截至 2022 年，預測：截至 2032 年。

按地區定位

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區和非洲。

包含的資料類型

銷售量、平均售價、手術例數、市場規模和成長趨勢。

本報告旨在透過將定價和銷售量分析與對全球血管治療領域血栓管理演變的實用見解相結合，為策略規劃、產品定位和競爭基準分析提供支援。

目標市場及區隔

• 本報告涵蓋全球周邊血栓治療市場，並按設備類型進一步細分如下：

傳統血栓除去裝置

這些裝置透過抽吸和提取等方法機械地去除血栓，可用於動脈和靜脈治療。

藥物血栓除去裝置

這些系統將機械血栓破壞與溶栓治療支持相結合，並在某些深層靜脈栓塞症(DVT) 和肺動脈栓塞(PE) 的治療流程中繼續發揮至關重要的作用。

導管導引溶栓治療

此部分包括基於導管的輸送系統，用於在指定的治療時間內將溶栓劑直接輸送到血栓部位。

每個細分市場均根據銷售量、平均售價和總市場價值進行分析，並包括截至 2032 年的預測和截至 2022 年的歷史數據。這種細分反映了周邊血栓治療中使用的主要治療方法，並有助於清楚地了解機械療法、混合療法和藥物療法之間的市場發展。

競爭分析

Inari Medical憑藉其ClotTriever和FlowTriever兩款設備迅速佔了顯著的市場佔有率。這兩款設備均無需溶栓藥物即可使用，並能顯著縮短患者的治療時間。 FlowTriever於2018年核准，是第二款核准的專門用於治療肺動脈栓塞的設備，並迅速獲得了較大的市場佔有率，部分原因是其價格高於EkoSonic等老款產品。 ClotTriever適用於周邊血管疾病，包括治療深層靜脈栓塞症（DVT），滿足了市場另一個快速成長的需求。憑藉在靜脈栓塞和肺動脈栓塞（PE）治療領域的強勁勢頭，Inari Medical有望繼續擴大其市場佔有率。

Penumbra 繼續專注於傳統血栓切除領域，提供 INDIGO CAT、Separator 和 Pump MAX 系列產品。這些設備主要用於動脈和靜脈手術，使 Penumbra 在抽吸血栓切除術流程中佔穩固地位。雖然本次分析未包含 Pump MAX主機本身，但其相關的導管系列產品仍持續支持 Penumbra 在傾向於採用傳統血栓切除術的醫院和介入實驗室中的地位。

2019年8月，波士頓科學公司透過收購BTG公司，鞏固了在周邊血栓治療領域的地位。在收購前，BTG在藥物機械取栓領域佔主導地位，其EkoSonic產品佔了該領域近三分之二的市場佔有率，並引領美國整體市場。收購後，波士頓科學公司成為整體市場的主要競爭對手之一，並在兩個成長最快的治療領域——深層靜脈栓塞症栓塞（DVT）和肺動脈栓塞（PE）——仍然保持著較高的市場佔有率。 AngioJet周圍血栓切除系統佔了周圍血栓切除術（PMT）領域的剩餘市場佔有率，使波士頓科學公司在混合血栓切除術領域也佔了至關重要的地位。

整體而言，市場競爭格局受到以下因素的影響：治療速度加快，溶解度降低或不降低溶解度的治療程序；靜脈血栓栓塞症治療的強勁成長；以及在傳統和藥物機械工作流程中提供產品的能力。

科技和醫療治療的發展趨勢

周邊血栓治療領域最重要的趨勢之一是微創血管內技術的日益普及。醫生擴大採用基於導管的血栓切除術和溶栓治療，而不是僅僅依賴開放性手術或長期藥物輸注。

另一個主要趨勢是治療方法逐漸轉向不使用溶栓藥物或減少溶栓藥物用量。無需使用大量溶栓藥物即可機械清除血栓的裝置正受到關注，因為它們可以縮短治療時間並減少出血風險。

靜脈介入治療的重要性也不斷提高。深層靜脈栓塞症（DVT）和肺動脈栓塞（PE）現在是市場上的主要成長領域，針對這些適應症專門設計的新器材正在研發中，而不是簡單地改造現有的動脈系統。

最後，高階設備的推出正在改變市場的價值結構。雖然並非所有細分市場的手術量都顯著成長，但高價值的機械血栓切除系統正在推動整體市場成長。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球分析。

一份長達 68 頁的詳細市場分析、市場區隔和預測數據報告。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

到 2032 年，全球周邊血栓管理市場最大的成長機會在哪裡？

傳統血栓切除術、藥物血栓切除術和導管溶栓術的相對重要性變化有多快？

深層靜脈栓塞症(DVT)、肺動脈栓塞(PE) 和維持透析通路將在長期市場擴張中扮演什麼角色？

資本投資需求、昂貴的醫療設備以及更簡單、成本更低的替代方案如何限制了其普及？

在非溶解性血栓切除術、抽吸系統和藥物治療領域，哪些競爭者佔最有利的地位？

微創血栓切除術的廣泛應用將如何改變周邊血管介入治療的未來？

iData Research 的「全球周邊血栓管理市場報告」透過詳細的市場細分、定價分析、競爭資訊和市場預測，解答了這些問題。利用這份報告，您可以對標競爭對手，了解治療需求，並在周邊血管介入治療這一成長最快的領域之一制定策略。

目錄

圖表清單

調查方法

• 步驟 1：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 步驟 4：進行初步調查
• 步驟 5：調查與分析：建立基準估計值
• 步驟 6：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟 9：客戶回饋與市場監測

全球關稅的影響

周邊血栓管理市場

• 摘要整理
  • 全球周邊血栓管理市場概覽
  • 競爭分析
  • 目標程式
  • 目標市場
  • 目標區域
• 介紹
• 手術次數
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 周邊血栓管理市場整體狀況
  • 傳統血栓切除器械市場
  • 藥物輔助機械血栓切除裝置市場
  • 導管溶栓治療裝置的市場
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Peripheral Thrombus Management Market Report

The global peripheral thrombus management market was valued at $1.3 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 7.3% to reach $2.2 billion by 2032.

• The full report suite on the global market for peripheral thrombus management covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a forward-looking view of market expansion. This description follows the same structure and progression used in the attached example document, adapted to the procedural, competitive and pricing dynamics of the peripheral thrombus management market .

This report provides detailed analysis of the global peripheral thrombus management market, including unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and forecasts through 2032, with historical data to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors. The market is further segmented into traditional thrombectomy devices, pharmacomechanical thrombectomy devices and catheter-directed thrombolysis.

Peripheral thrombus management is becoming a more important part of vascular intervention because physicians are increasingly using minimally invasive endovascular techniques to remove or dissolve clots in peripheral arteries and veins. These procedures offer a less invasive alternative to open surgery and can help improve treatment speed, reduce hospital stay length and align with the broader move toward image-guided interventional care. As device technology improves and procedural experience expands, these approaches are moving closer to standard use in selected thrombotic conditions.

The market is also being reshaped by a shift in physician preference. While lytic drug therapy remains less expensive in many cases, mechanical thrombectomy offers clinical benefits that are driving greater adoption. These include faster reperfusion, shorter treatment times and avoidance of the bleeding risks associated with thrombolytic drugs. At the same time, new premium devices are pushing average selling prices upward, especially in deep vein thrombosis and pulmonary embolism treatment.

Market Overview

The global peripheral thrombus management market includes devices and techniques used to remove, disrupt or dissolve thrombus in peripheral arteries and veins. These devices are used in a broad procedural setting that includes deep vein thrombosis, pulmonary embolism, dialysis access maintenance and other thrombotic vascular conditions where restoring patency quickly is clinically important.

This is a market that sits at the intersection of urgency, efficiency and procedural evolution. In many thrombotic cases, time matters. Delayed reperfusion can worsen tissue ischemia, extend hospital stay and increase the risk of complications. Because of this, physicians increasingly value tools that can achieve faster clot removal while avoiding some of the limitations associated with thrombolytic drugs alone. This has helped support the shift from purely pharmaceutical treatment toward a wider mix of mechanical and pharmacomechanical intervention.

The market is also influenced by the broader trend toward minimally invasive care. Endovascular treatment is now preferred in many vascular settings because it can reduce trauma, lower recovery burden and fit more naturally into modern interventional workflows. Peripheral thrombus management devices fit well within this trend. They allow physicians to treat clot burden through catheter-based access rather than open surgery, often with greater control and faster turnaround.

The market is also being shaped by a stronger focus on venous disease and pulmonary embolism. Historically, many vascular device markets were more centered on arterial intervention. Today, DVT and PE treatment are becoming more commercially important, especially as newer thrombectomy systems target these conditions directly and offer procedural speed advantages without relying on lytics. This is changing both the competitive landscape and the value mix of the market.

Overall, the peripheral thrombus management market reflects a move toward faster, more targeted and less invasive clot treatment. That shift is supporting one of the stronger growth profiles among peripheral vascular device categories.

Market Drivers

Mechanical Thrombectomy Advantage

One of the most important drivers in the global peripheral thrombus management market is the clinical advantage offered by mechanical thrombectomy. While pharmaceutical thrombolysis can be more cost-effective upfront, mechanical thrombectomy provides several benefits that are becoming more important in actual clinical practice.

Some patients cannot undergo thrombolytic therapy or do not respond adequately to it. In those cases, mechanical thrombectomy offers a more practical solution. These devices can also restore perfusion more quickly than lytic therapy in ischemic limbs and other urgent settings. Faster reperfusion can reduce downstream complications and shorten hospital stays, which improves the overall treatment pathway for both the patient and the provider.

Another major benefit is the reduced reliance on lytic drugs. Because thrombolytics carry a significant bleeding risk, many physicians are becoming more selective about when they use them. Mechanical thrombectomy allows operators to avoid or reduce lytic use in many cases, which supports greater confidence in treating complex patients. As thrombectomy penetration rises, the market also benefits from higher average selling prices, especially where premium devices are being adopted in place of lower-cost lytic approaches.

Increased Hemodialysis Patients

The increasing number of patients requiring hemodialysis is another important driver of market demand. As diabetes becomes more prevalent due to aging populations and rising obesity rates, the number of patients progressing to kidney failure continues to grow. This creates greater need for dialysis access procedures and access maintenance.

Thrombus management devices play a role in restoring or maintaining patency in dialysis access pathways. As this patient population expands globally, demand for AV access treatment also rises. This supports recurring need for thrombectomy and related interventions, especially in settings where access preservation is a critical part of long-term patient management.

Growing Adoption of Minimally Invasive Endovascular Techniques

A broader structural driver is the increasing adoption of minimally invasive endovascular thrombus management. Physicians are increasingly using thrombectomy and thrombolysis techniques delivered through catheter-based approaches rather than relying on open surgery or purely conservative management. This trend aligns with wider healthcare preferences for shorter recovery times, lower procedural trauma and more efficient treatment pathways.

As endovascular techniques improve, these procedures are becoming more acceptable across a broader set of clinical settings. They are also becoming more standardized in selected thrombotic conditions. This is especially important because it means the market is benefiting not only from device innovation, but from an overall procedural shift in how thrombus is managed.

Market Limiters

Capital Equipment

One of the biggest limiters in the global peripheral thrombus management market is the requirement for capital equipment in some device systems. Certain thrombectomy platforms depend on associated consoles, pumps or other hardware. This creates a high initial cost and also consumes space that is often limited in hospitals and interventional suites.

For facilities managing tight budgets or limited physical capacity, this can slow adoption. Even when the clinical value of the disposable device is clear, the need to support it with capital equipment can complicate the purchasing decision. This is particularly relevant outside the largest centers or in markets where procedure volumes may not justify the investment.

High Cost Versus Alternatives

Another major limiter is the cost of thrombectomy relative to alternative treatment pathways. Thrombectomy procedures can be much more expensive than drug treatment, balloon angioplasty, stenting or even simple manual aspiration using guide catheters and long sheaths. Because hospitals remain highly cost conscious, they will often use lower-cost alternatives when those methods are considered clinically acceptable.

This creates a practical cap on adoption. Even in a market with strong growth, not every thrombotic case will move to premium thrombectomy devices. Hospitals and physicians continuously balance speed, effectiveness, risk and cost. That means high-value devices must justify themselves against simpler and cheaper options on a case-by-case basis.

Native Fistula Preference

In Europe especially, native fistulae remain the preferred means of dialysis access. Native fistulae generally have better patency rates than artificial grafts, and that reduces the later need for thrombectomy procedures. This has a limiting effect on parts of the market tied to dialysis access maintenance.

There is also a regulatory and usage nuance here. Mechanical thrombectomy devices are often approved mainly for use in artificial grafts, while their use in native fistulae may be off-label. Even though native fistulae may at times be more appropriate for mechanical thrombectomy than drug therapy, the broader preference for fistula creation still reduces the total frequency of access-related clot intervention compared with a market built more heavily around artificial grafts.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, product positioning and competitive benchmarking by combining pricing and unit analysis with practical insight into how thrombus management is evolving across global vascular care.

Markets Covered and Segmentation

• The report covers the Global Peripheral Thrombus Management Market, further segmented by device type into:

Traditional Thrombectomy Devices

These devices remove thrombus mechanically, often through aspiration or extraction-based methods, and are used across arterial and venous applications.

Pharmacomechanical Thrombectomy Devices

These systems combine mechanical clot disruption with thrombolytic support and remain important in selected DVT and PE workflows.

Catheter Directed Thrombolysis

This segment includes catheter-based delivery systems used to administer thrombolytic drugs directly to the clot site over a defined treatment interval.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the major treatment approaches used in peripheral thrombus management and supports a clear view of how the market is shifting between mechanical, hybrid and drug-based care.

Competitive Analysis

Inari Medical has rapidly gained significant market share through its ClotTriever and FlowTriever devices. Both are capable of use without thrombolytics, which has helped reduce treatment times substantially for patients. FlowTriever, approved in 2018, became the second approved device specifically designed for pulmonary embolism treatment and captured a substantial share due in part to premium pricing relative to older alternatives such as EkoSonic. ClotTriever, indicated for use in the peripheral vasculature including DVT treatment, serves another fast-growing area of the market. With strong momentum in both venous and PE care, Inari Medical is well positioned to continue increasing its market share.

Penumbra remained focused on the traditional thrombectomy segment, offering the INDIGO CAT, Separator and Pump MAX product families. These devices are used primarily in arterial and venous applications and give Penumbra a strong position in aspiration-based thrombectomy workflows. Although the Pump MAX console itself is not included in this analysis, the associated catheter families continue to support Penumbra's relevance in hospitals and interventional labs that prefer traditional thrombectomy approaches.

Boston Scientific strengthened its position in peripheral thrombus management following its August 2019 acquisition of BTG. Prior to the acquisition, BTG led the total U.S. market through a dominant position in pharmacomechanical thrombectomy, where EkoSonic held close to two-thirds of the segment. After the acquisition, Boston Scientific became one of the leading competitors in the total market and retained strong share in two of the fastest-growing treatment areas, DVT and PE. The AngioJet Peripheral Thrombectomy System represents the remaining share of the PMT segment, keeping Boston Scientific highly relevant in hybrid thrombectomy approaches.

Overall, competition in the market is being shaped by the shift toward faster, lytic-light or lytic-free procedures, by strong growth in venous thromboembolism treatment and by the ability to offer products across both traditional and pharmacomechanical workflows.

Technology and Practice Trends

One of the most important trends in peripheral thrombus management is the growing adoption of minimally invasive endovascular techniques. Physicians are increasingly using catheter-based thrombectomy and thrombolysis instead of relying only on open surgery or prolonged drug infusion.

Another major trend is the move toward lytic-free or reduced-lytic treatment. Devices that can remove clot mechanically without heavy thrombolytic use are gaining attention because they can shorten treatment time and reduce bleeding-related concerns.

Venous intervention is also becoming more important. DVT and PE are now major growth areas in the market, and new devices are being designed specifically for these indications rather than adapted from older arterial-focused systems.

Finally, premium device adoption is changing the value profile of the market. Even when procedure counts are not rising dramatically in every subsegment, higher-value mechanical thrombectomy systems are pushing overall market growth upward.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

68 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the strongest growth opportunities in the global peripheral thrombus management market through 2032?

How fast are traditional thrombectomy, pharmacomechanical thrombectomy and catheter-directed thrombolysis shifting in relative importance?

What role do DVT, PE and dialysis access maintenance play in long-term market expansion?

How do capital equipment requirements, high device pricing and simpler lower-cost alternatives limit adoption?

Which competitors are best positioned in lytic-free thrombectomy, aspiration-based systems and pharmacomechanical treatment?

How is the broader shift toward minimally invasive clot removal changing the future of peripheral vascular intervention?

The Global Peripheral Thrombus Management Market Report from iData Research answers these questions with detailed segmentation, pricing analysis, competitive intelligence and market forecasting. Use it to benchmark competitors, understand procedural demand and support strategy in one of the fastest-growing categories within peripheral vascular intervention.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Peripheral Thrombus Management Market

• 13.1 Executive Summary
  • 13.1.1 Global Peripheral Thrombus Management Market Overview
  • 13.1.2 Competitive Analysis
  • 13.1.3 Procedures Included
  • 13.1.4 Markets Included
  • 13.1.5 Regions Included
• 13.2 Introduction
• 13.3 Procedure Numbers
• 13.4 Market Overview
  • 13.4.1 By Segment
  • 13.4.2 By Region
• 13.5 Market Analysis And Forecast
  • 13.5.1 Total Peripheral Thrombus Management Market
  • 13.5.2 Traditional Thrombectomy Device Market
  • 13.5.3 Pharmacomechanical Thrombectomy Device Market
  • 13.5.4 Catheter Directed Throbolysis Device Market
• 13.6 Drivers And Limiters
  • 13.6.1 Market Drivers
  • 13.6.2 Market Limiters
• 13.7 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 13-1: Peripheral Thrombus Management Market, Global, 2025 & 2032
• Chart 13-2: Peripheral Thrombus Management Procedures, Global, 2025
• Chart 13-3: Peripheral Thrombus Management Procedures by Region, Global, 2022 - 2032
• Chart 13-4: Peripheral Thrombus Management Market by Segment, Global, 2022 - 2032
• Chart 13-5: Peripheral Thrombus Management Market by Region, Global, 2022 - 2032
• Chart 13-6: Leading Competitors, Peripheral Thrombus Management Market, Global, 2025

LIST OF FIGURES

• Figure 13-1: Peripheral Thrombus Management Procedures Covered
• Figure 13-2: Peripheral Thrombus Management Markets Covered
• Figure 13-3: Peripheral Thrombus Management Regions Covered, Global (1 of 2)
• Figure 13-4: Peripheral Thrombus Management Regions Covered, Global (2 of 2)
• Figure 13-5: Peripheral Thrombus Management Procedures by Region, Global, 2022 - 2032
• Figure 13-6: Peripheral Thrombus Management Procedures by Country, North America, 2022 - 2032
• Figure 13-7: Peripheral Thrombus Management Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-8: Peripheral Thrombus Management Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-9: Peripheral Thrombus Management Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-10: Peripheral Thrombus Management Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-11: Peripheral Thrombus Management Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-12: Peripheral Thrombus Management Procedures by Country, Middle East, 2022 - 2032
• Figure 13-13: Peripheral Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-14: Peripheral Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-15: Peripheral Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-16: Peripheral Thrombus Management Procedures by Country, Africa, 2022 - 2032
• Figure 13-17: Peripheral Thrombus Management Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 13-18: Peripheral Thrombus Management Market by Region, Global, 2022 - 2032 (US$M)
• Figure 13-19: Peripheral Thrombus Management Market, Global, 2022 - 2032
• Figure 13-20: Units Sold by Region, Peripheral Thrombus Management Market, Global, 2022 - 2032
• Figure 13-21: Average Selling Price by Region, Peripheral Thrombus Management Market, Global, 2022 - 2032 (US$)
• Figure 13-22: Market Value by Region, Peripheral Thrombus Management Market, Global, 2022 - 2032 (US$M)
• Figure 13-23: Traditional Thrombectomy Device Market, Global, 2022 - 2032
• Figure 13-24: Units Sold by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032
• Figure 13-25: Average Selling Price by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032 (US$)
• Figure 13-26: Market Value by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032 (US$M)
• Figure 13-27: Pharmacomechanical Thrombectomy Device Market, Global, 2022 - 2032
• Figure 13-28: Units Sold by Region, Pharmacomechanical Thrombectomy Device Market, Global, 2022 - 2032
• Figure 13-29: Average Selling Price by Region, Pharmacomechanical Thrombectomy Device Market, Global, 2022 - 2032 (US$)
• Figure 13-30: Market Value by Region, Pharmacomechanical Thrombectomy Device Market, Global, 2022 - 2032 (US$M)
• Figure 13-31: Catheter Directed Thrombolysis Device Market, Global, 2022 - 2032
• Figure 13-32: Units Sold by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032
• Figure 13-33: Average Selling Price by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032 (US$)
• Figure 13-34: Market Value by Region, Traditional Thrombectomy Device Market, Global, 2022 - 2032 (US$M)
• Figure 13-35: Leading Competitors, Peripheral Thrombus Management Market, Global, 2025